SG Americas Securities LLC Buys New Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

SG Americas Securities LLC purchased a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,028 shares of the biotechnology company’s stock, valued at approximately $39,000.

A number of other large investors also recently added to or reduced their stakes in the company. ExodusPoint Capital Management LP raised its holdings in shares of Aldeyra Therapeutics by 11.7% in the 2nd quarter. ExodusPoint Capital Management LP now owns 22,495 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 2,364 shares during the period. Cetera Advisor Networks LLC grew its position in Aldeyra Therapeutics by 18.3% in the 2nd quarter. Cetera Advisor Networks LLC now owns 17,049 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 2,641 shares in the last quarter. Boothbay Fund Management LLC increased its stake in Aldeyra Therapeutics by 22.2% during the first quarter. Boothbay Fund Management LLC now owns 16,521 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 2,996 shares during the period. Ameriprise Financial Inc. lifted its position in shares of Aldeyra Therapeutics by 2.3% during the first quarter. Ameriprise Financial Inc. now owns 143,432 shares of the biotechnology company’s stock worth $1,424,000 after purchasing an additional 3,200 shares in the last quarter. Finally, Citigroup Inc. boosted its stake in shares of Aldeyra Therapeutics by 8.4% in the first quarter. Citigroup Inc. now owns 48,586 shares of the biotechnology company’s stock valued at $482,000 after purchasing an additional 3,766 shares during the period. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ALDX shares. Oppenheimer upgraded shares of Aldeyra Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a report on Wednesday, April 3rd. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Tuesday, April 2nd. Finally, StockNews.com upgraded Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 29th.

Insider Buying and Selling

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc purchased 8,374 shares of the business’s stock in a transaction on Monday, April 1st. The shares were bought at an average cost of $3.25 per share, for a total transaction of $27,215.50. Following the completion of the purchase, the insider now directly owns 8,601,960 shares in the company, valued at $27,956,370. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, major shareholder Perceptive Advisors Llc acquired 8,374 shares of the business’s stock in a transaction on Monday, April 1st. The shares were bought at an average price of $3.25 per share, with a total value of $27,215.50. Following the completion of the acquisition, the insider now owns 8,601,960 shares in the company, valued at $27,956,370. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Todd C. Brady sold 97,914 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $3.27, for a total transaction of $320,178.78. Following the completion of the transaction, the chief executive officer now owns 1,556,622 shares of the company’s stock, valued at approximately $5,090,153.94. The disclosure for this sale can be found here. Over the last quarter, insiders bought 355,933 shares of company stock worth $1,473,245. Corporate insiders own 7.30% of the company’s stock.

Aldeyra Therapeutics Stock Performance

ALDX stock opened at $3.86 on Monday. The company’s 50 day moving average price is $3.59 and its 200 day moving average price is $3.25. The firm has a market capitalization of $227.35 million, a price-to-earnings ratio of -6.03 and a beta of 1.51. Aldeyra Therapeutics, Inc has a fifty-two week low of $1.42 and a fifty-two week high of $11.97.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.13. Equities analysts forecast that Aldeyra Therapeutics, Inc will post -0.14 EPS for the current fiscal year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.